natgillin/translations-raw huggingface dataset:
The suspension is packaged in a 2-ml Type I glass cartridge, sealed at one end with a (bromobutyl) rubber seal/cap combination (combiseal), and at the other end with a (bromobuty) rubber plunger. 
Suspenzija je pakirana v 2-ml vložek iz stekla tipa I, ki je na eni strani zaprt s kombinacijo (brombutilne) gumijaste zapore/pokrovčka (kombinirana zapora) in na drugi strani z (brombutilnim) gumijastim batom.
The following interaction studies have been conducted using 10 mcg immediate-release exenatide but not prolonged-release exenatide formulations: 
Sledeče študije medsebojnega delovanja so bile narejene za uporabo 10 μg eksenatida v obliki s takojšnim sproščanjem, in ne za uporabo eksenatida v obliki s podaljšanim sproščanjem:
The powder in one chamber must be mixed with the solvent in the other chamber of the pre-filled pen. 
Prašek v enem prekatu je potrebno zmešati z vehiklom v drugem prekatu napolnjenega injekcijskega peresnika.
Hold the pen up straight with the orange cap toward the ceiling. 
Držite peresnik pokonci in obrnjen tako, da oranžni pokrovček gleda proti stropu.
1 vial of 2 mg exenatide 
1 vialo z 2 mg eksenatida
Lift the vial with the orange connector now attached out of its package. 
Dvignite vialo - oranžni povezovalec bo sedaj odstranjen iz ovojnine.
Clinical experience in patients with moderate renal impairment (creatinine clearance 30 to 50 ml/min) is limited. 
Kliničnih izkušenj pri bolnikih z zmerno okvaro ledvic (očistek kreatinina 30 do 50 ml/min) je malo.
Fasting lipids Prolonged-release exenatide has shown no negative effects on lipid parameters. 
Za eksenatid v obliki s podaljšanim sproščanjem niso ugotovili nobenega neugodnega učinka na parametre lipidov.
For subcutaneous use only 
Samo za subkutano uporabo
The absorption properties of exenatide reflect the extended release properties of the prolonged-release exenatide formulation. 
Absorpcijske lastnosti eksenatida odražajo podaljšano sproščanje eksenatida v obliki s podaljšanim sproščanjem.
When this medicine is used with a medicine that contains a sulphonylurea, episodes of low blood sugar (hypoglycaemia, generally mild to moderate) can occur. 
Pri uporabi tega zdravila sočasno z zdravilom, ki vsebuje sulfonilsečnino, lahko pride do epizod nizkega sladkorja v krvi (hipoglikemije, na splošno blage do zmerno hude).
Pre-filled pen is for single-use only. 
Napolnjen injekcijski peresnik je le za enkratno uporabo.
Patients on pioglitazone gained weight (Table 4). 
Bolniki na pioglitazonu so pridobili na telesni masi (Preglednica 4).
The dose of your sulphonylurea medicine may need to be reduced while you use this medicine. 
Med vašo uporabo tega zdravila boste morda morali znižati odmerek vašega zdravila s sulfonilsečnino.
• hypoglycaemia (low blood sugar) when this medicine is used with a medicine that does not contain a sulphonylurea 
• hipoglikemija (nizek krvni sladkor) v primeru uporabe z zdravilom, ki ne vsebuje sulfonilsečnine
Powder poly (D,L-lactide-co-glycolide) sucrose 
Prašek poli (D,L-laktid koglikolid) saharoza
However, as renal function generally declines with age, consideration should be given to the patient's renal function (see Renal impairment) (see section 5.2). 
Ker pa se delovanje ledvic z leti slabša, je pozornost potrebno posvetiti bolnikovemu delovanju ledvic (glejte Okvara ledvic) (glejte poglavje 5.2).
Hold the syringe near the black dashed Dose Line. 
Injekcijsko brizgo držite blizu črne odmerne črte.
There have been spontaneously reported events of acute pancreatitis with prolonged-release exenatide. 
Obstajajo tudi spontana poročila o primerih akutnega pankreatitisa pri uporabi eksenatida v obliki s podaljšanim sproščanjem.
You may see a few drops of liquid on the needle or in the cover. 
Na igli ali na pokrovčku lahko opazite nekaj kapljic tekočine.
Its use is commonly associated with gastrointestinal adverse reactions, including nausea, vomiting, and diarrhoea. 
Uporabo zdravila pogosto povezujejo z neželenimi učinki na prebavila, vključno z navzeo, bruhanjem in drisko.
In interaction studies of the effect of immediate-release exenatide on digoxin and lisinopril there were no clinical relevant effects on Cmax or AUC, however, a delay in tmax of about 2 h was observed. 
V študijah medsebojnega delovanja učinka eksenatida v obliki s takojšnim sproščanjem na digoksin in lizinopril niso ugotovili nobenih klinično pomembnih učinkov na Cmax ali AUC.
Rate based on twelve prolonged-release exenatide completed long-term efficacy and safety studies n = 2868 total. 
Pogostnost na podlagi dvanajstih dokončanih dolgoročnih študij učinkovitosti in varnosti eksenatida v obliki s podaljšanim sproščanjem, n skupaj = 2868.
Hold Upright 
Ne zamrzujte.
Clinically and statistically significantly more subjects on prolonged-release compared to immediate-release exenatide patients achieved an HbA1c reduction of ≤ 7 % or < 7 % in the two studies (p <0.05 and p ≤0.0001, respectively). 
Klinično in statistično značilno več oseb, ki so se zdravile z eksenatidom v obliki s podaljšanim sproščanjem, je v primerjavi z eksenatidom v obliki s takojšnim sproščanjem doseglo znižanje HbA1c ≤ 7 % ali < 7 % v obeh študijah (p < 0,05 in p ≤ 0,0001).
§nominal p-value <0.001. 
§nominalni p < 0,001.
Pull the plunger down beyond the black dashed Dose Line. 
Bat povlecite navzdol preko s črno označene odmerne črte.
• Refer to the Common questions and answers 
• glejte Pogosta vprašanja in odgovori
Fasting lipids The prolonged-release exenatide formulations have shown no negative effects on lipid parameters. 
Za eksenatid v oblikah s podaljšanim sproščanjem niso ugotovili nobenega neugodnega učinka na parametre lipidov.
Step 3: Inject your dose 
3. korak: Injicirajte odmerek
• hypoglycaemia (low blood sugar) when taken with a medicine that contains a sulphonylurea. 
• hipoglikemija (nizek krvni sladkor) v primeru uporabe z zdravilom, ki vsebuje sulfonilsečnino.
For all patients completing the uncontrolled study extension of 7 years (n = 122 of 258 patients included in the extension phase), HbA1c gradually increased over time from Week 52 onwards, but was still reduced compared to baseline after 7 years (-1.5%). 
Pri vseh bolnikih, ki so zaključili 7-letno nekontrolirano podaljšano študijo (n = 122 od 258 bolnikov, ki so bili vključeni v podaljšano fazo), se je HbA1c skozi obdobje od 52. tedna naprej postopno povečeval, toda po 7 letih je bil še vedno znižan v primerjavi z izhodiščem (-1,5 %).
Unless a trained person can help to inject this medicine it is not recommended for people who are blind or cannot see well. 
To zdravilo ni priporočljivo za slepe in slabovidne osebe, če nimajo na voljo usposobljene osebe za pomoč pri injiciranju.
To reduce the risk of hypoglycaemia associated with the use of a sulphonylurea, reduction in the dose of sulphonylurea may be considered (see sections 4.2 and 4.4). 
Da se izognemo tveganju za hipoglikemijo, povezano z uporabo sulfonilsečnine, je potrebno razmisliti o zmanjšanju odmerka sulfonilsečnine (glejte poglavji 4.2 in 4.4).
Multi-pack of 3 x (4 single dose kits). 
Veliko pakiranje 3 x (4 enoodmerni seti).
B. Twist knob to release injection button. 
B. Zasukajte gumb, da boste sprostili gumb za injiciranje.
Keep pushing on the plunger with your thumb until it stops, and hold it in place. 
Nadaljujte s pritiskanjem palca na bat, dokler se ne ustavi, ter ga nato držite.
Exenatide slows gastric emptying, thereby reducing the rate at which meal-derived glucose appears in the circulation. 
Eksenatid upočasni praznjenje želodca, s čimer zmanjša hitrost, s katero se glukoza iz obroka pojavi v krvnem obtoku.
The concurrent use of prolonged-release exenatide with D-phenylalanine derivatives (meglitinides), alpha-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors or other GLP-1 receptor agonists has not been studied. 
Sočasne uporabe eksenatida v obliki s podaljšanim sproščanjem z derivati D-fenilalanina (meglitinidi), zaviralci alfa-glukozidaze, zaviralci dipeptil peptidaze-4 ali drugih zaviralcev receptorjev GLP-1 niso preučevali.
In clinical studies of prolonged-release exenatide, approximately 45% of patients had low titre antibodies to exenatide at study endpoint. 
Na koncu kliničnih študij z eksenatidom v obliki s podaljšanim sproščanjem je imelo približno 45 % bolnikov nizke titre protiteles proti eksenatidu.
The results of long-term clinical studies of prolonged-release exenatide are presented below; these studies comprised 1356 subjects treated with prolonged-release exenatide, 52% men and 48% women; 230 subjects (17%) were ≥ 65 years of age. 
Te študije so vključevale 1356 oseb zdravljenih z eksenatidom v obliki s podaljšanim sproščanjem, 52 % moških in 48 % žensk; 230 oseb (17 %) je bilo starih ≥ 65 let.
Insert the needle into your skin (subcutaneously). 
Zabodite iglo v kožo (subkutano).
• injection site reactions 
• reakcije na mestu injiciranja
In a 28-week double-blind study, prolonged-release exenatide added to insulin glargine alone or with metformin was compared to placebo added to insulin glargine alone or with metformin. 
V 28-tedenski dvojno slepi študiji so eksenatid v obliki s podaljšanim sproščanjem, dodan insulinu glarginu samemu ali skupaj z metforminom, primerjali s placebom, dodanem insulinu glarginu samemu ali skupaj z metforminom.
Remove the needle and replace it with the spare needle from your kit. 
Odstranite iglo in jo zamenjajte z dodatno iglo, ki jo imate v setu.
INR should be monitored during initiation of prolonged-release exenatide therapy in patients on warfarin and/or cumarol derivatives (see sections 4.4 and 4.8). 
Pri bolnikih, ki jemljejo varfarin in/ali derivate kumarola je med uvajanjem zdravljenja eksenatida v obliki s podaljšanim sproščanjem potrebno spremljati vrednosti INR (glejte poglavji 4.4 in 4.8).
Remember: You must take your injection of Bydureon immediately after mixing it. 
Zapomnite si: Injekcijo Bydureon morate uporabiti takoj po mešanju.
The concurrent use of prolonged-release exenatide formulations with D-phenylalanine derivatives (meglitinides), alpha-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors or other GLP-1 receptor agonists has not been studied. 
Sočasne uporabe eksenatida v oblikah s podaljšanim sproščanjem z derivati D-fenilalanina (meglitinidi), zaviralci alfa-glukozidaze, zaviralci dipeptil peptidaze-4 ali drugih zaviralcev receptorjev GLP-1 niso preučevali.
Each single-dose kit consists of one vial containing 2 mg exenatide powder, one pre-filled syringe containing 0.65 ml solvent, one vial connector, and two injection needles. 
Vsak enoodmerni set vsebuje eno vialo z 2 mg praška eksenatida, eno napolnjeno injekcijsko brizgo z 0,65 ml vehikla, en povezovalec viale in dve injekcijski igli.
Frequency reported from the 28-week controlled treatment period of the prolonged-release exenatide as add-on to insulin glargine study (N=231). 
Pogostnost, zabeležena med 28-tedenskim kontroliranim obdobjem zdravljenja v študiji eksenatida v obliki s podaljšanim sproščanjem kot dodatka insulinu glarginu (N = 231).
• does not leak, 
• ne pušča,
In a 2-year rat carcinogenicity study with prolonged-release exenatide, an increased incidence of C-cell adenomas and C-cell carcinomas was observed at doses ≥ 2-fold the human systemic exposure based on AUC. 
V 2-letni študiji karcinogenosti eksenatida v obliki s podaljšanim sproščanjem pri podganah so ob odmerkih, ki so bili na podlagi AUC ≥ 2-kratnik sistemske izpostavljenosti pri človeku, opažali večjo pojavnost adenomov celic C in karcinomov celic C. Klinični pomen teh ugotovitev trenutno ni znan.
Striped Label 
Črtasta nalepka
Each single-dose kit contains one vial of 2 mg exenatide, one pre-filled syringe of 0.65 ml solvent, one vial connector, and two injection needles (one spare). 
Vsak enoodmerni set vsebuje eno vialo z 2 mg eksenatida za suspenzijo za injiciranje, eno predhodno napolnjeno injekcijsko brizgo z 0,65 ml vehikla za injiciranje, en povezovalnik viale in dve injekcijski igli (ena dodatna).
Additional reductions in postprandial concentrations were also observed. 
Opazili so tudi nadaljnje znižanje v koncentraciji glukoze po jedi.
Compared with insulin glargine treatment, prolonged-release exenatide demonstrated a superior change in HbA1c, significantly lowered mean body weight and was associated with fewer hypoglycaemic events (Table 5). 
V primerjavi z insulinom glarginom je zdravljenje z eksenatidom v obliki s podaljšanim sproščanjem pokazalo večjo spremembo v HbA1c, značilno znižalo srednjo vrednost telesne mase in je bilo povezano z redkejšimi hipoglikemičnimi dogodki (Preglednica 5).
To be sure you get your full dose, press and hold the pen against your skin. 
Da boste prepričani, da ste dobili celoten odmerek, peresnik pritisnite ob kožo in ga držite pritisnjenega obnjo.
Prolonged-release exenatide should not be used during breast-feeding. 
Eksenatida v obliki s podaljšanim sproščanjem med dojenjem ne smemo uporabljati.
Withdrawal due to nausea or vomiting each occurred in < 1% for prolonged-release exenatide treated patients and 1% for immediate-release exenatide treated patients. 
Prekinitev zaradi navzee ali bruhanja je bila pri bolnikih, ki so se zdravili z eksenatidom v obliki s podaljšanim sproščanjem, < 1 %, in pri bolnikih, ki so se zdravili z eksenatidom v obliki s takojšnim sproščanjem,
After suspension The suspension must be injected immediately after mixing the powder and the solvent. 
Po suspendiranju Suspenzija mora biti injicirana nemudoma po mešanju praška in vehikla.
A clinically relevant effect of prolonged-release exenatide and immediate-release exenatide treated subjects was observed on HbA1c, regardless of the background anti-diabetic therapy in both studies. 
Klinično pomemben učinek na HbA1c je bil opažen pri bolnikih, ki so se zdravili z eksenatidom v obliki s podaljšanim sproščanjem ali eksenatidom v obliki s takojšnim sproščanjem, neodvisno od osnovnega antidiabetičnega zdravljenja, v obeh študijah.
How to use Bydureon 
Kako uporabljati zdravilo Bydureon
The expiration date is labelled EXP. 
Datum izteka roka uporabnosti je označen z
Remove one pen from the refrigerator and let it stand at room temperature for at least 15 minutes. 
Vzemite en peresnik iz hladilnika in ga vsaj 15 minut pustite na sobni temperaturi.
Slowly push 
Pritisnite počasi
*p-value < 0.01. 
*Vrednost p < 0,01.
The frequency of adverse reactions of prolonged-release exenatide identified from clinical studies and spontaneous reports (not observed in clinical studies, frequency not known) are summarised in Table 1 below. 
Preglednica 1, spodaj, povzema pogostnost neželenih učinkov eksenatida v obliki s podaljšanim sproščanjem, ugotovljenih v kliničnih študijah in na podlagi spontanih poročil (neopaženi v kliničnih študijah, neznana pogostnost).
You should use contraception if you could potentially become pregnant during treatment with this medicine. 
Če obstaja kakršna koli možnost, da bi med zdravljenjem s tem zdravilom zanosili, morate uporabljati kontracepcijo.
The finished medicinal product is comprised of the suspension-filled cartridge assembled into the pen device. 
Dokončano zdravilo obsega s suspenzijo napolnjen vložek, vstavljen v peresnik.
Compared with insulin glargine treatment, prolonged-release exenatide demonstrated a superior change in HbA1c, significantly lowered mean body weight and was associated with fewer hypoglycaemic events (Table 3). 
V primerjavi z insulinom glarginom je zdravljenje z eksenatidom v obliki s podaljšanim sproščanjem pokazalo večjo spremembo v HbA1c, značilno znižalo srednjo vrednost telesne mase in je bilo povezano z redkejšimi hipoglikemičnimi dogodki (Preglednica 3).
In the placebo-controlled study with insulin glargine, the change from baseline to Week 28 in fasting plasma glucose was -0.7 mmol/l for the prolonged-release exenatide group and -0.1 mmol/l for the placebo group. 
V študiji z insulinom glarginom, kontrolirani s placebom, je bila sprememba koncentracije glukoze v plazmi na tešče od izhodišča do 28. tedna v skupini z eksenatidom v obliki s podaljšanim sproščanjem -0,7 mmol/l in v skupini s placebom -0,1 mmol/l.
In the placebo-controlled study with insulin glargine, the change from baseline to Week 28 in systolic blood pressure was -2.6 mmHg for the prolonged-release exenatide group and -0.7 mmHg for the placebo group. 
V študiji z insulinom glarginom, kontrolirani s placebom, je bila sprememba sistoličnega krvnega tlaka od izhodišča do 28. tedna v skupini z eksenatidom v obliki s podaljšanim sproščanjem -2,6 mmHg in v skupini s placebom -0,7 mmHg.
When the medicine is mixed well, it should look cloudy. 
Ko je zdravilo dobro zmešano, mora izgledati motno.
• hypoglycaemia (low blood sugar) when taken with an insulin 
• hipoglikemija (nizek krvni sladkor) v primeru uporabe z insulinom
Prolonged-release exenatide demonstrated significantly greater weight reductions compared to sitagliptin. 
Eksenatid v obliki s podaljšanim sproščanjem je pokazal značilno večje znižanje telesne mase v primerjavi s sitagliptinom.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING 
PODATKI, KI MORAJO BITI NAVEDENI NA ZUNANJI OVOJNINI
Patients (%) achieving HbA1c ≤ 7% 62 
Bolniki (%), ki so dosegli HbA1c ≤ 7 % 62
In a 28-week open-label study, Bydureon BCise was compared to immediate-release exenatide in subjects on a diet and exercise programme alone or with a stable regimen of oral glucose-lowering medicinal products. 
V odprti 28-tedenski študiji so zdravilo Bydureon BCise primerjali z eksenatidom v obliki s takojšnjim sproščanjem pri bolnikih, ki so bili le na programu z dieto in telesno dejavnostjo ali na stabilni shemi zdravljenja s peroralnimi antidiabetiki.
C. Remove the needle cover, 
D. Odstranite prekrivni papirček s pokrovčka igle.
To inject your full dose, push down on the plunger with your thumb until it stops. 
Da boste injicirali celoten odmerek, pritisnite s palcem na bat, dokler se bat ne ustavi.
in either your stomach, thigh, or back of the arm. Each week you can use the same area of your body but choose a different injection site in that area. 
Vsak teden lahko uporabite isti predel telesa, vendar pa morate na tistem predelu izbrati drugo mesto za injiciranje.
Follow the Instructions for the User to prepare and inject your dose. 
Za pripravo in injiciranje odmerka upoštevajte Navodila za uporabnika.
Rare side effects • feeling jittery 
Redki neželeni učinki • občutek živčnosti
Each dual-chamber pen contains exenatide powder and solvent in a Type 1 glass cartridge sealed at one end with a chlorobutyl rubber stopper and an aluminium seal, and at the other end with a chlorobutyl rubber piston. 
En dvoprekatni injekcijski peresnik vsebuje prašek eksenatida in vehikel v steklenem vložku, narejenem iz stekla tipa I, ki je na eni strani zaprt z zamaškom iz klorobutilne gume in aluminijasto zaporo, na drugi strani pa z gumijastim batom iz klorobutilne gume.
The risk of hypoglycaemia was increased when prolonged-release exenatide was used in combination with a sulphonylurea in clinical studies. 
V kliničnih študijah je bilo tveganje za hipoglikemijo povečano ob sočasni uporabi eksenatida v obliki s podaljšanim sproščanjem s sulfonilsečnino.
Keep pushing down on the plunger with your thumb and shake vigorously. 
Nadaljujte s pritiskanjem navzdol in močno stresajte.
No dose adjustment is required based on age. 
Pri starejših prilagajanja odmerka ni potrebno.
Overall, 9.3% of patients treated with Bydureon BCise reported nausea during the controlled period of both clinical studies. 
V celoti je med kontroliranim obdobjem obeh kliničnih študij o navzei poročalo 9,3 % bolnikov, ki so bili zdravljeni z zdravilom Bydureon BCise.
The patient should be instructed to discard the pen safely after each injection. 
Bolniku je potrebno naročiti, naj po vsakem injiciranju peresnik varno zavrže.
Bydureon contains the active substance exenatide. 
Zdravilo Bydureon vsebuje učinkovino eksenatid.
Do not save it to use later. 
Ne smete ga shraniti za poznejšo uporabo.
Common Questions and Answers 
Pogosta vprašanja in odgovori
To mix, shake the pen hard until the white medicine is no longer on the bottom, top, or sides. 
Da boste zdravilo premešali, močno stresajte peresnik, dokler na dnu, na vrhu in ob straneh ni več belega zdravila.
The powder is packaged in a 3 ml Type I glass vial sealed with a chlorobutyl rubber stopper and an aluminium seal with a plastic flip-off cap. 
Prašek se nahaja v 3-mililitrski viali iz stekla tipa I s klorobutilnim gumijastim batom in aluminijastim pokrovčkom s plastičnim zamaškom.
Powder and solvent for prolonged-release suspension for injection. 
Prašek in vehikel za suspenzijo s podaljšanim sproščanjem za injiciranje.
A reduction in HbA1c was observed over the course of the trial with an overall treatment difference of -0.53% (prolonged-release exenatide vs. placebo). 
Med preskušanjem so opažali znižanje HbA1c; celotna razlika med terapevtskima skupinama je bila -0,53 % (eksenatid v obliki s podaljšanim sproščanjem v primerjavi s placebom).
Hydroxy methyl glutaryl coenzyme A reductase inhibitors Lovastatin AUC and Cmax were decreased approximately 40% and 28%, respectively, and tmax was delayed about 4 h when immediate-release exenatide was administered concomitantly with a single dose of lovastatin (40 mg) compared with lovastatin administered alone. 
Zaviralci hidroksimetilglutaril koencim A reduktaze Ob dajanju eksenatida v obliki s takojšnim sproščanjem sočasno z enkratnim odmerkom lovastatina (40 mg) sta se vrednosti AUC in Cmax v primerjavi z dajanjem lovastatina samega zmanjšali za približno 40 % in 28 % in tmax se je podaljšal za približno 4 ure.
Immune system disorders Anaphylactic reaction Metabolism and nutrition disorders Hypoglycaemia (with a sulphonylurea) 
Bolezni imunskega sistema anafilaktična reakcija Presnovne in prehranske motnje hipoglikemija (s sulfonilsečnino) hipoglikemija (z insulinom) zmanjšanje teka dehidracija
Use only the supplied needles with the pen. 
Uporabljajte le igle, ki so priložene peresniku.
Most adverse reactions associated with prolonged-release exenatide were mild to moderate in intensity. 
Večina neželenih učinkov, povezanih z eksenatidom v obliki s podaljšanim sproščanjem, je bila blaga do srednja huda.
There have been spontaneously reported cases of increased INR (International Normalized Ratio), sometimes associated with bleeding, with concomitant use of warfarin and exenatide (see section 4.5). 
Ob sočasnem jemanju varfarina z eksenatidom so spontano poročali o primerih zvišane vrednosti INR (internacionalno normalizirano razmerje), ki je bila včasih povezana s krvavitvami (glejte poglavje 4.5).
Please see the package leaflet and “Instructions for the User” for additional information on suspension and administration. 
Za dodatne informacije o suspendiranju in uporabi glejte navodilo za uporabo in “Navodila za uporabnika”.
Mean HbA1c (%) 
Povprečna vrednost HbA1c (%)
The pens must be stored flat. 
Peresnike je treba shranjevati v vodoravnem položaju.
Prolonged-release suspension for injection 4 single-dose pre-filled pens (BCise) BCise 
suspenzija s podaljšanim sproščanjem za injiciranje 4 napolnjeni injekcijski peresniki z enkratnim odmerkom (BCise) BCise
There were no events of major hypoglycaemia with Bydureon BCise. 
Med uporabo zdravila Bydureon BCise ni bilo hudih hipoglikemij.
A reduction in systolic blood pressure was observed in the studies with prolonged-release exenatide formulations (0.8 mmHg to 4.7 mmHg). 
V študijah z eksenatidom v oblikah s podaljšanim sproščanjem so opazili znižanje sistoličnega krvnega tlaka (0,8 mmHg do 4,7 mmHg).
Adverse reactions that have been observed with the prolonged-release exenatide but not in clinical studies with Bydureon BCise are also included in Table 1. 
Preglednica 1 vključuje tudi neželene učinke, ki so bili opaženi z eksenatidom v obliki s podaljšanim sproščanjem, vendar ne v kliničnih študijah z zdravilom Bydureon BCise.
Table 3: Results of one 28-week study of Bydureon BCise versus sitagliptin and placebo in combination with metformin (modified intent to treat patients 
Preglednica 3: Rezultati 28-tedenske študije zdravila Bydureon BCise v primerjavi s sitagliptinom in placebom v kombinaciji z metforminom (modificirana skupina bolnikov znamenom-zdravljenja